ACTRN12613001154796Not yet recruitingPhase 2
A phase 2 trial of cyclophosphamide as prophylaxis for graft-versus-host disease after HLA-identical allogeneic donor transplantation using reduced intensity conditioning therapy
Westmead Hospital0 sites24 target enrollmentStarted: October 16, 2013Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 24
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Non-randomised trial
- Primary Purpose
- Prevention
- Masking
- Open (masking not used)
Eligibility Criteria
- Ages
- 15 Years to 70 Years (—)
- Sex
- All
Inclusion Criteria
- •1. Age 15-70 years
- •2.High risk hematological malignancy suitable for treatment with an allogeneic transplant (acute leukaemia in first remission with poor risk cytogenetics or unfavourable gene mutation profile, or in second or subsequent remission, chronic myeloid leukaemia in first chronic phase not responding to tyrosine kinase inhibitor therapy, poor risk myelodysplastic syndrome, Hodgkin or non-Hodgkin lymphoma failing conventional therapy).
- •3.Suitable HLA-matched related donor (6/6 match for A, B, DRB1) or unrelated volunteer donor (8 locus match for A, B, C, and DRB1 at allelic level) identified and available.
Exclusion Criteria
- •1. Serious organ dysfunction or uncontrolled infection
- •2.HIV positive
- •3.Uncontrolled hepatitis B or C.
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Cyclophosphamide and Dexamethasone in combination with Ixazomib (ICD), in relpased or refractory multiple myeloma patients.Relasped and Refractory Mulitple MyelomaMedDRA version: 18.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2014-004511-36-GBniversity Of Leeds250
Active, not recruiting
Phase 1
Graft-versus-host response after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantatioWomen and men with a hematologic malignancy for which a reduced-intensity conditioning allo-SCT is indicatedMedDRA version: 19.0Level: PTClassification code 10053239Term: Prophylaxis against graft versus host diseaseSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2016-002129-12-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)88
Active, not recruiting
Not Applicable
An open-label, phase II study of cyclophosphamide, lenalidomide and dexamethasone (CLD) for previously treated patients with AL amyloidosis - NDEUCTR2007-006037-13-ITOSPEDALE POLICLINICO S. MATTEO
Active, not recruiting
Phase 2
Short treatment with the drug cyclophosphamide in bowel cancerStage II-IVA diagnosed colorectal cancerBowel cancerCancerISRCTN12508004Cardiff University500
Completed
Phase 2
A parallel randomised phase II trial of cyclophosphamide, adriamycin, vincristine and prednisolone (CHOP) chemotherapy with or without Bortezomib in relapsed mantle cell lymphomaRelapsed or refractory mantle cell lymphomaMantle cell lymphomaCancerISRCTN20159589Plymouth Hospitals NHS Trust (UK)90